Company intelligence / Profile preview

NanoPalm

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

NanoPalm is developing AI-designed, self-targeting lipid nanoparticle systems for in vivo gene therapies targeting rare and genetic diseases. Their lead programs include biorobots aimed at removing mutated genes responsible for sickle cell disease and delivering therapies directly to retinal cells in retinitis pigmentosa. The company has been selected by Charles River Laboratories’ Advanced Therapy Incubator Program, reflecting international recognition but has not yet reported human clinical trial results.

Therapeutic areas: Rare DiseasesOphthalmologyHematology
Modalities: Lipid nanoparticles (LNPs)Gene therapy vectorsNucleic acid delivery (RNA, DNA)
Industry: Biotech

Drug pipeline

3 assets

Cochleate BioRobot

Pre-clinical

Indications: Genetic diseases

2 more assets in the full pipeline.

Request access →

Partnerships

Charles River Laboratories – participant in Advanced Therapy Incubator ProgramLafana Holding – Saudi investment firm supporting nomination to incubator program

Beyond the preview

Go deeper on NanoPalm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoPalm.

Explore the full profile